Search

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Artificial intelligence co-creation for educational learning tools and targeted simulators

Artificial intelligence (AI)-powered tools are becoming increasingly common within clinical practice and medical education, and using AI in simulation as a pure learning tool and for assessment has been widely discussed. Targeted, efficient use of such tools has been shown...

IN FOCUS - The achievements and lasting effects of VISION 2020

Blindness is a major public health problem globally. The first estimate of global blindness by the World Health Organization (WHO) in 1972 provided a figure of 10 to 15 million, which was considered an underestimate [1]. In 1999, an extraordinary...

Retinoblastoma management update (part 1): clinical features, diagnosis and genetics

The first of a two part series, this article will discuss the clinical features, diagnosis and genetic aspects of retinoblastoma. Manoj Parulekar is based at Birmingham Children’s Hospital, one of the two designated national retinoblastoma and paediatric ocular oncology treatment...